SUPN: Supernus Revenue and Sales Volume

The development of Supernus Pharmaceuticals (SUPN) relies on the automation of production lines and packaging. The success of Qelbree and new Parkinson's disease treatments to replace legacy revenue streams will be the key growth drivers. The company's sales volume confirms this trend, where the 1.37 metric determines the parameter status. However, aggressive generic pressure and the risk of failures in neurobiology pose serious threats to stability.
Comprehensive metric breakdowns and analytics for Supernus Pharma (SUPN)

To filter for high-quality assets, investors must distinguish long-term fundamental trends from short-term market noise. This indicator measures total trading revenue, reflecting how the business adapts to macro cycles, which, based on current sales figures for Supernus Pharmaceuticals (SUPN), allows for an assessment of Qelbree's expansion efficiency and the pace of niche capture within CNS therapy and pediatric psychiatry.